thalidomide has been researched along with CACH Syndrome in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simon, AJ | 1 |
| Lev, A | 1 |
| Zhang, Y | 1 |
| Weiss, B | 1 |
| Rylova, A | 1 |
| Eyal, E | 1 |
| Kol, N | 1 |
| Barel, O | 1 |
| Cesarkas, K | 1 |
| Soudack, M | 1 |
| Greenberg-Kushnir, N | 1 |
| Rhodes, M | 1 |
| Wiest, DL | 1 |
| Schiby, G | 1 |
| Barshack, I | 1 |
| Katz, S | 1 |
| Pras, E | 1 |
| Poran, H | 1 |
| Reznik-Wolf, H | 1 |
| Ribakovsky, E | 1 |
| Simon, C | 1 |
| Hazou, W | 1 |
| Sidi, Y | 1 |
| Lahad, A | 1 |
| Katzir, H | 1 |
| Sagie, S | 1 |
| Aqeilan, HA | 1 |
| Glousker, G | 1 |
| Amariglio, N | 1 |
| Tzfati, Y | 1 |
| Selig, S | 1 |
| Rechavi, G | 1 |
| Somech, R | 1 |
1 other study available for thalidomide and CACH Syndrome
| Article | Year |
|---|---|
Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects.
Topics: Animals; Ataxia; Brain Neoplasms; Calcinosis; Central Nervous System Cysts; Disease Models, Animal; | 2016 |